Algorithms for primary care: An evidence-based approach to the pharmacotherapy of depression and anxiety disorders

Primary Psychiatry

Volumn 11, Issue 6, 2004, Pages 55-78

  Stein, Dan J ^a,b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; KAVA EXTRACT; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; PHENELZINE; PINDOLOL; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALCOHOL ABUSE; ALGORITHM; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; EVIDENCE BASED MEDICINE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MEDICAL PRACTICE; MELANCHOLIA; MOOD DISORDER; PATIENT COMPLIANCE; POLYPHARMACY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEASONAL AFFECTIVE DISORDER;

EID: 3042811397     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (171)

1. Kessler RC, McGonagle KC, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
2. Rush AJ. Clinical practice guidelines: Good news, bad news, or no news? Arch Gen Psychiatry. 2001;50;483-490.
3. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry. 1999;156:5-10.
4. Eddy DM. Clinical Decision-Making: From Theory to Practice. Sudbury, MA: Jones and Bartless; 1996.
5. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
6. Stein DJ, Patterson B, Hollander E. Expert systems for psychiatric pharmacotherpy. Psych Annals. 1994;24:37-41.
7. Fawcett J, Stein DJ, Jobson KO. Textbook of Treatment Algorithms in Psychopharmacology. Chichester UK: John Wiley & Sons; 1999.
8. Klein DF. Clinical psychopharmacological practice: the need for a developing research base. Arch Gen Psychiatry. 1993;50:491-494.
9. Daniels A, Biesma R, Otten J, et al. Ambivalence of primary health care professionals towards the South African guidelines for hypertension and diabetes. S Afr Med J. 2000;90:1206-1211.
10. Peveler R, Kendrick T. Treatment delivery and guidelines in primary care. Br Med Bull. 2001;57:193-206.
11. Bauer MS. A review of quantitative studies of adherence to mental health clinical practice guidelines. Harv Rev Psychiatry. 2002;10:138-153.
12. Rush AJ, Crismon ML, Toprac MG, et al. Implementing guidelines and systems of care: experiences with the Texas Medication Algorithm Project (TMAP). J Pract Psychiatry Behav Health. 1999;5:75-86.
13. Freeman AC, Sweeney K. Why general practitioners do not implement evidence: qualitative study. BMJ. 2001;323:1100.
14. Stein DJ, Xin Y, Osser D, Li X, Jobson K. Clinical psychopharmacology guidelines: different strokes for different folks. World J Biol Psychiatry. 2002;3:64-67.
15. Bero L, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote implementation of research findings by health care professionals. BMJ. 1998;317:465-468.
16. Field MJ, Lohr KN. Clinical Practice Guidelines: Directions for a New Program. Washington, DC: National Academy Press; 1990.
17. Persons JB, Thase ME, Crits-Christoph, P. The role of psychotherapy in the treatment of depression: review of two practice guidelines. Arch Gen Psychiatry. 1996;53:283-290.
18. Parker G, Roy K, Eyers K. Cognitive behavior therapy for depression? Choose horses for courses. Am J Psychiatry. 2003;160:825-834.
19. Grilli R, Freemantle N, Minozzi S, Domenighetti G, Finer D. Mass media interventions: effects on health services utilization. Cochrane Database Syst Rev. 2002;1:CD000389.
20. Gilbody S, Whitty P, Grimshaw J, Thomas, R. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA. 2003;289:3145-3151.
21. de Lima S, Hotopf M. A comparison of active drugs for the treatment of dysthymia. Cochrane Database Syst Rev. 2003;3:CD004047.
22. Nobile M, Cataldo G, Marino C, Molteni M. Diagnosis and treatment of dysthymia in children and adolescents. CNS Drugs. 2003;17:927-946.
23. Hazell P, O'Connell P, Heathcote D, Henry D. Tricyclic drugs for depression in child and adolescents. Cochrane Database Syst Rev. 2003;4: CD002317.
24. Ramchandani P. Treatment of major depressive disorder in children and adolescents. BMJ. 2004;328:3-4.
25. Ambrosini PJ. A review of pharmacotherapy of major depression in children and adolescents. Psychiatr Services. 2000;51:627-633.
26. Birmaher B, Brent DA, Benson RS. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders: American Academy of child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1998;37:1234-1238.
27. Gilbody SM, House AO, Sheldon TA. Routinely administered questionnaires for depression and anxiety: systematic review. BMJ. 2001;322:406-409.
28. Williams JW Jr, Noël PH, Cordes JA, Ramirez G, Pignone M. Is this patient clinically depressed? JAMA. 2002;287:1160-1170.
29. Montano CB. Recognition and treatment of depression in a primary care setting. J Clin Psychiatry. 1994;55(suppl):18-34.
30. Srisurapanont M, Yatham LN, Zis AP. Treatment of acute bipolar depression; a review of the literature. Can J Psychiatry. 2002;40:533-544.
31. Zomberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol. 1993;13:397-408.
32. Hall RC, Gardner ER, Popkin MK, et al. Unrecognized physical illness prompting psychiatric admission: a prospective study. Am J Psychiatry. 1981;183:629-635.
33. Katon W. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54:216-226.
34. Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry. 1994;151:1735-1739.
35. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58:19-36.
36. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol. 1994;9:139-143.
37. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Rae AM. A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatr Scand. 2003;108:20-23.
38. Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry. 2003;53:680-690.
39. Kantor SJ, Glassman AH. Delusional depression: natural history and response to treatment. Br J Psychiatry. 1977;131:351-360.
40. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45:129-137.
41. Lonnqvis J, Shivo S, Syvalahti E, et al. Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord. 1994:169-177.
42. Lam RW, Gorman CP, Michalon M, et al. Multicentre, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry. 1995;152:1765-1770.
43. Partonen T, Lonnqvist J. Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord. 1996;41:93-99.
44. Smith WT, Longboorg PD, Glaudin V, et al. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry. 1998;155:1339-1345.
45. Furukawa TA, Streiner DL, Young LT. Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev. 2001;2:CD001026.
46. Naranjo CA, Knoke DM. The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. J Clin Psychiatry. 2001;62(suppl 20):18-25.
47. Wisner KL, Zarin DA, Holmbroe ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry. 2000;157:1933-1940.
48. Altshuler LL, Cohen LS, Moline ML, et al. The expert consensus guideline series: treatment of depression in woman. Postgrad Med. 2001;3(spec no): 1-116.
49. Hoffbrand S, Howard L, Crawley H. Antidepressant drug treatment for postnatal depression. Cochrane Database Syst Rev. 2001;2:CD002018.
50. Miller LJ. Postpartum depression. JAMA. 2002;287:762-765.
51. Schneider LS, Small GW, Hamilton SH, et al. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial: Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry. 1997;5:97-106.
52. Gill D, Hatcher S. Antidepressants for depression in medical illness. Cochrane Database Syst Rev. 2000;4:CD001312.
53. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311-320.
54. Roose SP, Glassman AH, Giardina EG, et al. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry. 1974;44:273-275.
55. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351-359.
56. Shabnam GN, Th C, Kho DH, Ce C. Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev. 2003;3:CD003465.
57. Bains J, Birks JS, Dening TR. The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev. 2002;4:CD003944.
58. Anderson IM. Meta-analytic studies on new antidepressants. Br Med Bull. 2001;57:161-178.
59. Gelenberg AJ, Chesen CL. How fast are antidepressants. J Clin Psychiatry. 2000;61:712-721.
60. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. Br J Psychiatry. 2000;177:292-302.
61. MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003;326:1014.
62. Birmaher B. Should we use antidepressant medications for children and adolescents with depressive disorders? Psychopharmacol Bull. 1998;34:35-39.
63. Guaiana G, Barbui C, Hotopf M. Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev. 2003;2:CD004186.
64. Furukawa T, McGuire H, Barbui C. Low dosage tricyclic antidepressants for depression. Cochrane Database Syst Rev. 2003;3: CD003197.
65. Barbui C, Hotopf M, Freemantle N, et al. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev. 2000;4:CD002791.
66. Mittmann N, Herrmann N, Einarson TR, et al. The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord. 1997;46:191-217.
67. Wilson K, Mottram P, Sivanranthan A, Nightingale A. Antidepressants versus placebo for depressed elderly. Cochrane Database Syst Rev. 2001;2:CD000561.
68. Linde K, Mulrow CD. St John's wort for depression. Cochrane Database Syst Rev. 2000;2: CD000448.
69. Shaw K, Turner K, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2002;1:CD003198.
70. Franchini L, Serretti A, Gasperini M, et al. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res. 1998;32:255-259.
71. Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J Psychopharmacol. 1997;11:72-82.
72. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151:1372-1374.
73. Kraus RP, Diaz P, McEachran, A. Managing rapid metabolizers of antidepressants. Depress Anxiety. 1996;4:320-327.
74. Donovan SJ, Quitkin FM, Stewart JW, et al. Duration of antidepressant trials: clinical and research implications. J Clin Psychopharmacol. 1994;14:64-66.
75. Quitkin FM, Petkova EP, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry. 2003;160:734-740.
76. Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995;152:1500-1503.
77. Reimherr FW, Amsterdam JD, Quitkin FM, et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 1998;155:1247-1253.
78. Geddes JR, Carney SM, Davies S, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:653-661.
79. Reynolds CF 3rd, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999;281:39-45.
80. Nelson JC. Treatment of antidepressant non-responders: augmentation or switch. J Clin Psychiatry. 1998;59(suppl):35-41.
81. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 18):4-11.
82. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry. 2001;62(suppl 18):12-17.
83. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled trial comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50:387-393.
84. Joffe RT, Sokolov STH. Thyroid hormone treatment of primary unipolar depression: a review. Int J Neuropsychopharmacol. 2000;3:143-147.
85. Taylor MJ, Carney S, Geddes J, Goodwin G. Folate for depressive disorders. Cochrane Database Syst Rev. 2003;2:CD003390.
86. Nelson JC. Augmentation strategies with serotonergic-noradrenergic combinations. J Clin Psychiatry. 1998;59(suppl):65-68.
87. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649-659.
88. Krishnan KRR. Comorbidity and depression treatment. Biol Psychiatry. 2003;53:701-706.
89. Grote NK, Frank E. Difficult-to-treat depression: the role of contexts and comorbidities. Biol Psychiatry. 2003;53:660-670
90. Thase ME, Rush J, Howland RH, et al. Doubleblind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002;59:233-239.
91. Nierenberg AA, Feighner JP, Rudoph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994;14:419-423.
92. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry. 1993;150:118-123.
93. Martin JL, Barbanoj MJ, Schlaepfer TE, et al. Transcranial magnetic resonance stimulation for treating depression. Cochrane Database Syst Rev. 2002;2:CD003493.
94. George MS, Rush AJ, Sackheim HA, Marangell LB. Vagus nerve stimulation (VNS): utility in neuropsychiatric disorders. Int J Neuropsychopharmacol. 2003;6:73-83.
95. Klaiber EL, Broverman DM, Vogel W, et al. Estrogen therapy for severe persistent depression in women. Arch Gen Psychiatry. 1979;36:550-557.
96. Stahl SM. Augmentation of antidepressants by estrogen. Psychopharmacol Bull. 1998;34:319-321.
97. Lawrie, T A, Herxheimer, A, and Dalton, K. Oestrogens and progestogens for preventing and treating postnatal depression. Cochrane Database Syst Rev. 2000;2:CD001690.
98. Tohen M, Shelton R, Tollefson GD, et al. Olanzapine plus fluoxetine: double-blind and open-label results in treatment-resistant major depressive disorder. Eur Neuropsychopharmacology. 1999;9(suppl 5):S246.
99. Joffe RT, Levitt AJ. Relationship between antidepressant partial and nonresponse and subsequent response to antidepressant augmentation. J Affect Disord. 1999;52:257-259.
100. Roy-Byrne PP, Katon W. Generalized anxiety disorder in primary care: the precursor/modifier pathway to increased health care utilization. J Clin Psychiatry. 1997;58S:34-38.
101. Schneider F, Weiss U, Kessler C, et al. Subcortical correlates of differential classical conditioning of aversive emotional reactions in social phobia. Biol Psychiatry. 1999;45:863-871.
102. Posternak MA, Mueller TI. Assessing the risks and benefits of benzodiazepines for anxiety disorders inpatients with a history of substance abuse of dependence. Am J Addict. 2000;10:48-68.
103. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Eng J Med. 1997;336:258-262.
104. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002;53:39-49.
105. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, for the WFSBP Task Force on Treatment Guidelines for Anxiety Obsessive-Compulsive, and Posttraumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive, and posttraumatic stress disorders. World J Biol Psychiatry. 2002;3:171-199.
106. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001;62S11:53-58.
107. Gould R, Otto MW, Pollack MH, et al. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analysis. Behavior Therapy. 1997;28:285-305.
108. Gale C, Oakley-Brown M. Anxiety disorder: clinical review. Br Med J. 2000;321:1204-1207.
109. Kapczinski F. Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003;2:CD003592.
110. Ferreri M, Hantouche EG. Recent clinical trials of hydroxyzine in generalized anxiety disorder. Acta Psychiatr Scand. 1998;393(suppl):102-108.
111. DeMartinis N, Rynn M, Rickels K, et al. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J Clin Psychiatry. 2000;61:91-94.
112. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003;1: CD003383.
113. Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry. 2001;62(suppl 12):5-9.
114. Schweizer W, Rickels K, Uhlenhuth EH. Issues in the long-term treatment of anxiety disordersychopharmacology. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation. New York, NY: Raven Press; 1995.
115. Castenada R, Sussman N, Westreich L, et al. A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. J Clin Psychiatry. 1996;57:207-212.
116. Schadé A, Marquenie LA, van Balkom AJ, de Beurs E, van Dyck R, van den Brink W. Do comorbid anxiety disorders in alcohol-dependent patients need specific treatment to prevent relapse? Alcohol Alcohol. 2003;38:255-262.
117. Thompson PM. Generalized anxiety disorder treatment algorithm. Psych Annals. 1996;26:227-232.
118. Dupont RL, Rice DP, Shiraki S, et al. Economic costs of obsessive-compulsive disorder. Med Interface. 1995;8:102-109.
119. Stein DJ, Hollander E. Textbook of Anxiety Disorders, Washington, DC: American Psychiatric Press; 2002.
120. Hawkridge S, Stein DJ. Risk-benefit assessment of drug therapies for anxiety disorders in children and adolescents. Drug Saf. 1998;19:283-297.
121. Bernstein GA, Shaw K, for the Work Group on Quality Issues. Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 1997;36(suppl 10):69-84.
122. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. New Eng J Med. 1993;328:1398-1405.
123. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol. 1995;10:45-49.
124. van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2000;15(suppl 2):15-24.
125. Stein DJ, Zungu-Dirwayi N, van der Linden GJ, Seedat S. Pharmacotherapy for posttraumatic stress disorder. Cochrane Database of Systematic Rev. 2000;4:CD002795.
126. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;59S:47-54.
127. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2000;61(suppl 5):60-66.
128. Ballenger JC, Davidson JA, Lecrubier Y, et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry. 1998;59:54-60.
129. Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002;106:163-167.
130. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry, 1992;49:290-300.
131. Stein DJ, Stein MB, Goodwin W, Hunter B. The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and less generalized social anxiety disorder. Psychopharmacology. 2001;158:267-272.
132. Goddard AW, Brouette T, Almai A, Jerry P, Woods SW, Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry. 2001;58:681-686.
133. Noyes R, Perry P. Maintenance treatment with antidepressants in panic disorder. J Clin Psychiatry. 1990;51(suppl):24-30.
134. Southwick SM, Yehuda R. The interaction between pharmacotherapy and psychotherapy in the treatment of posttraumatic stress disorder. Am J Psychotherapy. 1993;47:404-411.
135. Pollack MH, Otto MW, Kaspi S, et al. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry. 1994;55:200-205.
136. Tesar GE, Rosenbaum JF. Successful use of clonazepam in patients with treatment-resistant panic disorder. J Nerv Ment Dis. 1986;174:477-482.
137. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20:467-471.
138. Tiffon L, Coplan JD, Papp LA, et al Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. J Clin Psychiatry. 1994;55:66-69.
139. Zamorski MA, Albucher RC. What to do when SSRIs fail: eight strategies for optimizing treatment of panic disorder. Am Fam Physician. 2002;66:1477-1484.
140. Hirschmann S, Dannon PN, Iancu I, et al. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000;20:556-559.
141. Davidson JRT, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13:423-428.
142. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin Psychopharmacol. 1999;19:341-348.
143. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controllled, crossover study. Am J Psychiatry. 2001;158:1725-1727.
144. Stein DJ, Seedat S, van der Linden G, Kaminer D. Pharmacotherapy of posttraumatic stress disorder. In: Davidson J, Nutt D, Zohar J, eds. Posttraumatic Stress Disorder: Assessment and Management. London, UK: Martin Dunitz; 2000.
145. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45:1226-1229.
146. Altamura AC, Pioli R, Vitto M, et al. Venlafaxine in social phobia: a study in selective serotonin reuptake non-responders. Int Clin Psychopharmacol. 1999;14:239-245.
147. Aarre TF. Phenelzine efficacy in refractory social anxety disorder: a case series. Nord J Psychiatry. 2003;57:313-315.
148. Stein DJ, Hollander E. Serotonin reuptake inhibitors in obsessive-compulsive disorder and related disorders. In: Feighner J, Boyer WF, eds. Selective Serotonin Reuptake Inhibitors: Advances in Basic Research and Clinical Practice. 2nd ed. New York, NY: John Wiley: 1996.
149. Stein DJ, Hollander E, Rowland C, Serebro P, Roberts M. Quality of life and pharmacoeconomic aspects or obsessive-compulsive disorder: a South African survey. S Afr Med J. 1996;86:1579-1585.
150. Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry. 1998;155:264-271.
151. Broocks A, Hohagen, F. Psychotherapy in OCD. In: Fineberg N, Marazziti D, Stein, DJ, eds. Obsessive-Compulsive Disorder: A Practical Guide. London, UK: Martin Dunitz; 2001.
152. Geller DA, Biederman J, Stewart SE, et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry. 2003;160:1919-1928.
153. King RA, Leonard H, March J, for the Work Group on Quality Issues. Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1998;37(suppl 10):27-45.
154. Hawkridge S, Stein DJ, Bouwer C. Combining neuroleptics with serotonin specific reuptake inhibitors in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 1996;35:703-704.
155. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive compulsive disorder. Int Clin Psychopharmacol. 1995;10:11-18.
156. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002;22:309-317.
157. Stein DJ. Neurobiology of the obsessive-compulsive spectrum of disorders. Biol Psychiatry. 2001;47:296-304.
158. Pato MT, Hill JL, Murphy DL. A clomipramine dosage reduction study in the course of long-term treatment of obsessive compulsive disorder patients. Psychopharmacol Bull. 1990;26:211-214.
159. Stein DJ, Fineberg N, Seedat S. An integrated approach to the treatment of OCD. In: Fineberg N, Marazziti D, Stein DJ. Obsessive-Compulsive Disorder: A Practical Guide. London, UK: Martin Dunitz; 2001.
160. McDougle CJ, Goodman WK, Leckman JF. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51:302-308.
161. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794-802.
162. Ravizza L, Barzega G, Bellino S, et al. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull. 1996;32:677-682.
163. Stein DJ, Bouwer C, Hawkrid S, et al. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry. 1997;58:119-122.
164. Marrazitti D, Dell'Osso L, Gemignani A, et al. Citalopram in refractory obsessive-compulsive disorder: an open study. Int Clin Psychopharmacol. 2001;16:215-219.
165. Hollander E, Mullen L, DeCaria CM, et al. Obsessive compulsive disorder, depression, and fluoxetine. J Clin Psychiatry. 1991;52:418-422.
166. Ananth J, Burgoyne K, Smith M, et al. Venlafaxine for treatment of obsessive-compulsive disorder. Am J Psychiatry. 1995;152:1832.
167. Koran LM, Sallee, FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry. 1997;154:396-401.
168. Bystritsky A, Munford PR, Rosen RM, et al. A preliminary study of partial hospital management of severe obsessive-compulsive disorder. Psychiatry Serv. 1996;47:170-174.
169. Martuza RL, Chiocca EA, Jenike MA, et al. Stereotactic radiofrequency thermal cingulotomy for obsessive-compulsive disorder. J Neuropsychiatry. 1990;2:331-336.
170. Maletzky B, McFarland B, Burt A. Refractory obsessive compulsive disorder and ECT. Convuls Ther. 1994;10:34-42.
171. Martin JL, Barbanoj MJ, Perez V, Sacristan M. Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder. Cochrane Database Syst Rev. 2003;3:CD003387.